Cartesian Therapeutics (RNAC) Other financing activities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 10 years of Other financing activities data on file, last reported at $279000.0 in Q1 2026.

• On a quarterly basis, Other financing activities rose 52.46% year-over-year to $279000.0 in Q1 2026; TTM through Mar 2026 was $96000.0, a 99.92% decrease from a year earlier, with the FY2024 full-year figure at $124.4 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at $279000.0, up from -$268000.0 in the prior quarter.
• Over the last five years, Other financing activities for RNAC reached as high as $121.6 million in Q3 2024 and fell as low as -$268000.0 in Q3 2025.
• Historically, Other financing activities has averaged $12.5 million across 4 years, with a median of $95500.0 in 2022.
• Across the five-year window, Other financing activities soared 91.03% in 2022 and tumbled 100.22% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$46000.0 in 2022, then soared by 264363.04% to $121.6 million in 2024, then tumbled by 100.22% to -$268000.0 in 2025, then jumped by 204.1% to $279000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $279000.0 in Q1 2026, -$268000.0 in Q3 2025, and $85000.0 in Q2 2025.